TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26234471
Drug: Rosehip powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosehip powder (3 capsules/day for 12 weeks)
Study: 26234471
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 identically appearing capsules/day for 12 weeks)
Study: 12687385
Drug: Once-daily beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily beclomethasone dipropionate (BDP), 400 micro g/day
Study: 12687385
Drug: Twice-daily beclomethasone
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily beclomethasone dipropionate (BDP), 400 micro g/day
Study: 1513607
Drug: Loracarbef 30
Normalized name: Loracarbef
DrugBank: Loracarbef (DB00447)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loracarbef 30 mg/kg/day in two divided doses for 10 days
Study: 1513607
Drug: Amoxicillin/clavulanate 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 40 mg/kg/day in three divided doses for 10 days
Study: 1513607
Drug: Loracarbef 30
Normalized name: Loracarbef
DrugBank: Loracarbef (DB00447)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loracarbef 30 mg/kg/day in two divided doses for 7 days
Study: 1513607
Drug: Amoxicillin 40
Normalized name: amoxicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 40 mg/kg/day in three divided doses for 7 days
Study: 24887336
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (0.5 µg/kg, 1 mL)
Study: 24887336
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (0.5 µg/kg, 20 mL)
Study: 11831545
Drug: 175 mg
Normalized name: caffeine 175 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg rofecoxib
Study: 6421778
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support (1800 kcal, 70 g protein) by naso-jejunal tube for 7-10 days
Study: 29437590
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Study: 27722221
Drug: Immediate non-occlusally
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate non-occlusally loaded implants
Study: 23169801
Drug: Intensive structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive structured care (computer assisted clinical profiling and risk target setting, intensified follow-up, stepwise drug titration)
Study: 19709689
Drug: pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (30 mg/d, n = 19)
Study: 19709689
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/d, n = 20)
Study: 19709689
Drug: placebo (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (medical nutrition therapy, n = 21)
Study: 15004572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ciprofloxacin and dexamethasone
Study: 15004572
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear solution (Tears Naturale)
Study: 11303266
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg
Study: 11303266
Drug: Cefixime, 400
Normalized name: Cefixime, 400 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime, 400 mg
Study: 11303266
Drug: Ciprofloxacin (MICs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (MICs > or = 4.0 microg/mL)
Study: 11303266
Drug: Ciprofloxacin (MICs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (MICs < 4.0 microg/mL)
Study: 9164216
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and chemotherapy (750 mg/m2 daily fluorouracil on days 1 to 5 and 29 to 33, and 15 mg/m2 mitomycin on day 1)
Study: 7232842
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and chemotherapy
Study: 2438902
Drug: Thermochemotherapy (hyperthermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermochemotherapy (hyperthermia combined with chemotherapy)
Study: 20397456
Drug: blood‐letting cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood‐letting cupping plus herbal medicine
Study: 17955168
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (traditional Chinese medicine)
Study: 8010718
Drug: High-dose folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folinic acid (FA) plus fluorouracil (FU)
Study: 2658897
Drug: Mezlocillin therapy
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mezlocillin therapy
Study: 2658897
Drug: Ampicillin-gentamicin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-gentamicin therapy
Study: 25099872
Drug: web- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: web- and text messaging-based intervention providing online feedback and tailored text messages, up to two weekly messages for 3 months
Study: 17309596
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 500 mg azithromycin per day for 3 days (N=25)
Study: 17309596
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 250 mg metronidazole tid for 14 days (N=24)
Study: 17309596
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 20 mg doxycycline bid for 3 months (N=20)
Study: 15125464
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for H. pylori-positive patients (Hp+/ome)
Study: 15125464
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/ome)
Study: 15125464
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/erad)
Study: 10457551
Drug: Single 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 800 mg injection of Pefloxacin (PF)
Study: 8574175
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (L-leucine 12 g, L-isoleucine 6 g, L-valine 6 g daily)
Study: 895002
Drug: new formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: new formulation isolating beta-acetyldigoxin from potassium-magnesium-aspartate
Study: 25788569
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human menopausal gonadotrophin (hMG) 37.5-75 IU per day
Study: 25788569
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg/day from Day 3-7
Study: 25788569
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human menopausal gonadotrophin (hMG)
Study: 19153941
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 to 8 mg daily)
Study: 16953261
Drug: Cetilistat 60
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 60 mg t.i.d.
Study: 19461584
Drug: Cetilistat 120
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 120 mg t.i.d.
Study: 16953261
Drug: Cetilistat 240
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 240 mg t.i.d.
Study: 16953261
Drug: Cetilistat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetilistat (all doses)
Study: 15372383
Drug: Bier block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bier block with methylprednisolone (40 mg) and lidocaine (10 mL of 2% solution)
Study: 11465642
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (21 mg patches)
Study: 9604636
Drug: Acupuncture (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (15 treatments over 3 months)
Study: 1620298
Drug: FUT-175 (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-175 (Group A: 20 mg every 12 hours for 4 days; Group B: 20 mg every 6 hours for 4 days; Group C: 40 mg every 6 hours for 4 days)
Study: 1620298
Drug: FUT-175 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-175 (higher doses: Groups B and C)
Study: 6366808
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg serrapeptase 3 times on the day before operation, once on the night of the operation and 3 times daily for 5 days after operation
Study: 23748117
Drug: Morphine (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.08 mg/kg)
Study: 24331381
Drug: Subcutaneous yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous yellow fever virus (YFV) vaccination
Study: 22529163
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl therapy
Study: 19243009
Drug: High-dose radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Study: 19243009
Drug: Low-dose radiosurgery
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Study: 19243009
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and low-dose radiosurgery
Study: 19243009
Drug: High-dose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose and low-dose radiosurgery
Study: 17544497
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of platinum-based chemotherapy followed by surgery (CT-S)
Study: 15066896
Drug: QI-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: QI-therapy
Study: 2540789
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (M series: 131 patients)
Study: 2540789
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance chemotherapy (NoM series: 134 patients)
Study: 2540789
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with complete response to initial chemotherapy (99 patients)
Study: 1954179
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy
Study: 836131
Drug: Foster care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foster care preparation
Study: 28375507
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (All three vaccines concurrently)
Study: 17007024
Drug: PegIFN‐alpha2a 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN‐alpha2a 180 mg subcutaneously once weekly for a year + Ribavirin 1200 mg
Study: 17007024
Drug: IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2a 3 MU 3 times weekly + Ribavirin 1200 mg
Study: 15017671
Drug: Rifampin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300 or 600 mg daily)
Study: 9292183
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal steroid (budesonide)
Study: 30886326
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg/day for 3 weeks)
Study: 19935373
Drug: Standard exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exposure everolimus (C0 3‐8 ng/mL) with low‐concentration cyclosporine A (C2 maintenance levels 350‐500 ng/mL)
Study: 19935373
Drug: Higher exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher exposure everolimus (C0 8‐12 ng/mL) with very low‐concentration cyclosporine A (C2 maintenance levels 150‐300 ng/mL)
Study: 16796694
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400 mg orally twice daily)
Study: 15273706
Drug: Intermediate-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cyclophosphamide (2 g/m(2)) plus lenograstim at 5 micrograms/kg (Cyclo-G-CSF group)
Study: 15273706
Drug: Lenograstim alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim alone at 10 micrograms/kg (G-CSF group)
Study: 15273706
Drug: Intermediate-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cyclophosphamide plus lenograstim (Cyclo-G-CSF group)
Study: 15273706
Drug: Lenograstim alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim alone (G-CSF group)
Study: 10860226
Drug: Low-tidal-volume ventilation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-tidal-volume ventilation (6 mL/kg)
Study: 10860226
Drug: Traditional-tidal-volume ventilation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional-tidal-volume ventilation (12 mL/kg)
Study: 25340383
Drug: Maximal medical
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal medical therapy
Study: 2866830
Drug: Dezocine 5
Normalized name: dezocine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 5 mg
Study: 2866830
Drug: Dezocine 10
Normalized name: dezocine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 10 mg
Study: 2871049
Drug: Dezocine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 2.5 mg
Study: 31494070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of APTD and anodal tDCS
Study: 24929926
Drug: Short-term Cognitive-Behavioral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term Cognitive-Behavioral Treatment (CBT)
Study: 18955835
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (154 mEq/l infusion)
Study: 18955835
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (0.9% solution)
Study: 16551862
Drug: 5,6-Dimethylxanthenone-4-acetic acid
Normalized name: 5,6-Dimethylxanthenone-4-acetic acid
DrugBank: Vadimezan (DB06235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) at 1,200 mg m(‐2)
Study: 10839291
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment in every arm
Study: 10839291
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment arm
Study: 6120703
Drug: flunitrazepam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam 0.03 mg/kg
Study: 6120703
Drug: midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.15 mg/kg
Study: 28063503
Drug: Glutamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.25 g/kg)
Study: 25891654
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of placental extract gel (group S)
Study: 23810688
Drug: Shenqi particle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi particle (9.6 g 3 times per day)
Study: 23810688
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg/d tapering to 0.17 mg/kg/d) and cyclophosphamide (total dose of 9-12 g/m²)
Study: 8198981
Drug: Recombinant interleukin
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interleukin 2 (rIL-2) therapy
Study: 2885357
Drug: Terfenadine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 300 mg bid for 3 days
Study: 2885357
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg bid for 3 days
Study: 2885357
Drug: Chlorpheniramine 8
Normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 8 mg three times a day for 3 days
Study: 29248859
Drug: Edoxaban and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban and Warfarin
Study: 28494895
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion at a dose of 2‐5μg/kg/min
Study: 28494895
Drug: Labetalol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol infusion at a dose of 0.5‐2mg/min
Study: 21129239
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ATP per day for 28 days
Study: 21129239
Drug: 1250 mg
Normalized name: bran 1250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg ATP per day for 28 days
Study: 21129239
Drug: 5000 mg
Normalized name: bran 5000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 mg ATP per day for 28 days
Study: 21129239
Drug: 5000 mg
Normalized name: bran 5000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 mg ATP on days 0 and 28
Study: 21129239
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg ATP per day for 28 days (control)
Study: 18850558
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% and timolol 0.5% (fixed combination)
Study: 18850558
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% and timolol 0.5% (fixed combination)
Study: 18850558
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% (adjunctive therapy)
Study: 18850558
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% (adjunctive therapy)
Study: 18850558
Drug: Brimonidine/timolol (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine/timolol (fixed combination)
Study: 11232987
Drug: Aspirin, ticlopidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, ticlopidine, and further intravenous heparin infusion for 48 hours following primary coronary stenting (Group 1)
Study: 11232987
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticlopidine without further heparin therapy following primary coronary stenting (Group 2)
Study: 6368610
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 250 mg q.i.d.
Study: 26110891
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 6% v/v EtOH (alcohol)
Study: 21480681
Drug: Static and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static and dynamic risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms, negative affect, craving, stress)
Study: 21480681
Drug: Static risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms)
Study: 19588684
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic epidural administration of bupivacaine with midazolam (group B)
Study: 19588684
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic epidural administration of bupivacaine (group A)
Study: 12798539
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 microg every 3 hours (group 2)
Study: 12798539
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of vaginal misoprostol 600 microg followed by oral misoprostol 200 microg every 3 hours (group 3)
Study: 10847283
Drug: Vicoprofen (ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicoprofen (ibuprofen 200 mg/hydrocodone 7.5 mg)
Study: 10847283
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine (acetaminophen 300 mg/codeine 30 mg)
Study: 1728377
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of mitomycin C (5 mg/m2, intravenously) every 6 weeks
Study: 1728377
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of mitomycin C (20 mg/m2, intravenously) every 6 weeks
Study: 20194878
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg/90 mg twice daily)
Study: 20194878
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg/75 mg once daily)
Study: 25660925
Drug: Ticagrelor therapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor therapy
Study: 17095943
Drug: Nutrient infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutrient infusion of Ensure at 1 kcal/min
Study: 17095943
Drug: Nutrient infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutrient infusion of Ensure at 2 kcal/min